Tomoko Kataoka

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

Kohei Nakachi, Masafumi Ikeda, Masaru Konishi et al. · The Lancet · 2023 · 232 citations

Medicine, Oncology, Surgery +11

Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial

Keiju Aokage, Kenji Suzuki, Hisashi Saji et al. · The Lancet Respiratory Medicine · 2023 · 227 citations · Full text

Medicine, Oncology, Surgery +8

Induction of apoptosis by gallic acid in human stomach cancer KATO III and colon adenocarcinoma COLO 205 cell lines.

Kazumi Yoshioka, Tomoko Kataoka, Toshiya Hayashi et al. · Oncology Reports · 2000 · 104 citations

Life Sciences, Cell Biology, Oncology +14

Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System

Chigusa Morizane, Nozomu Machida, Yoshitaka Honma et al. · JAMA Oncology · 2022 · 93 citations · Full text

Medicine, Oncology, Pharmacology +16

A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)

Masato Ozaka, Kohei Nakachi, Satoshi Kobayashi et al. · European Journal of Cancer · 2022 · 85 citations · Full text

Medicine, Oncology, Pharmacology +12